4月23日，由京东健康与赫力昂共同主办，人民健康提供平台支持的"无痛中国"生态共建暨全域合 作战略签约仪式在北京举行。此次合作双方以疼痛管理为切入点，依托京东健康在数字化诊疗、全渠道 供应链及用户全生命周期服务的核心优势，共同打造覆盖预防、诊断、治疗与康复的健康服务体系，为 大众提供更高效、便捷的疼痛管理解决方案，助力健康中国建设。 京东集团 SEC 委员、京东健康 CEO 金恩林在发言中回顾了与赫力昂过往九年的合作历程，同时表 示，"未来将依托京东健康的互联网医疗平台与全域流量优势，结合赫力昂在疼痛管理领域的专业经 验，构建服务闭环，助力患者全周期健康管理"。 赫力昂全球高级副总裁、中国大陆及香港地区总经理顾海英表示："我们也希望与京东一起树立医 药行业新标杆，推动疼痛管理领域的技术创新和服务升级，吸引更多的企业和机构关注疼痛管理，共同 为中国消费者的健康福祉贡献力量。" 活动当天上午，赫力昂与京东健康共同开展了以"无痛工作日"为主题的系列科普互动，现场设置丰 富多元的科普互动环节，包括疼痛冷知识问答、体态检测、疼痛管理体验、以及明星教练操课等，近距 离将无痛关怀带给职场人士，也将疼痛管理的专业支持与人文关 ...

Core Insights - JD Health released its 2024 Environmental, Social, and Governance (ESG) report, showcasing its sustainable development practices in the healthcare sector, emphasizing safety, efficiency, convenience, and warmth in health consumption experiences [1] Compliance and Governance - In 2024, JD Health established a comprehensive compliance system with a focus on user health, implementing a "three-line defense" and "five dimensions" approach to ensure compliance across all operations, including drug management and internet hospital services [3] - The company achieved ISO13485 certification for medical devices, expanding its compliance certifications to cover all business areas, including drug management and internet hospitals [3] - JD Health published standardized treatment paths for 43 diseases and established 4 core medical quality management systems, totaling 265 standardized treatment paths and 16 core systems over two years, enhancing the quality management of online medical services [3] Service Innovation - JD Health innovated its healthcare service model to meet diverse user needs, achieving an average of over 490,000 online consultations per day by the end of 2024 [4] - The company created a closed-loop service model integrating "doctor consultations," "home tests," "home delivery of medications," and "home nursing," allowing patients to access comprehensive healthcare services from home [4] - JD Health expanded its "JD Home Fast Testing" services to 12 cities, offering 149 home testing products, and launched nearly 40 home nursing projects through the "JD Nurse at Home" service [4] Technological Empowerment - JD Health accelerated the application of large model technology across various service scenarios, aiming to provide a seamless online and offline healthcare experience [7] - The company introduced several intelligent health services, including "KangKang" health assistant and "ChatGPT-like" AI psychological companion, enhancing the efficiency and accuracy of healthcare services [7] - JD Health's "Smart Doctor Assistant" became the most widely used intelligent diagnostic tool among doctors, improving clinical decision-making and patient management [7] Social Responsibility - JD Health deepened its corporate social responsibility initiatives, aiding 637 patients through its rare disease care program, with a total value of assistance reaching 6.24 million yuan [8] - The "Medical Heart Station" project, in collaboration with top medical institutions, provided support to over 23,000 patients, improving the healthcare experience for rare disease patients [8] - The company conducted 22 donation activities in 2024, donating over 1.53 million health items to rural communities and disaster relief efforts [10] - JD Health launched a "Expired Medicine Recycling" initiative, successfully collecting and professionally disposing of 11 tons of expired medications, engaging 57,000 users across 315 cities [10]

Financial Performance - JD Health reported a revenue of RMB 58,159,881 thousand for 2024, representing a 8.9% increase from RMB 53,529,941 thousand in 2023[9]. - The gross profit for 2024 was RMB 13,308,577 thousand, up from RMB 11,865,336 thousand in 2023, indicating a growth of 12.1%[9]. - The annual profit attributable to the owners of the company reached RMB 4,161,844 thousand, a significant increase of 94.3% compared to RMB 2,141,841 thousand in 2023[9]. - Revenue for the reporting period reached RMB 58.2 billion, representing an 8.6% year-over-year growth[23]. - Revenue increased by 8.6% from RMB 53.5 billion in 2023 to RMB 58.2 billion in 2024, driven by a 6.9% increase in sales of pharmaceutical and health products[39]. - Active user count as of December 31, 2024, reached 183.6 million, with an average of over 490,000 online consultations per day throughout 2024[23]. - Net profit increased from RMB 2.1 billion in 2023 to RMB 4.2 billion in 2024[49]. - Non-IFRS profit for 2024 was RMB 4,792,278 thousand, compared to RMB 4,135,439 thousand in 2023, reflecting a growth of about 16%[53]. Assets and Equity - Total assets increased to RMB 71,274,993 thousand in 2024 from RMB 64,288,300 thousand in 2023, marking an increase of 10.4%[10]. - The equity attributable to owners of the company rose to RMB 55,231,156 thousand in 2024, up 11.5% from RMB 49,355,752 thousand in 2023[10]. - Cash and cash equivalents increased from RMB 15 billion in 2023 to RMB 22.6 billion in 2024, marking a rise of approximately 50%[54]. - As of December 31, 2024, the company had no outstanding borrowings, indicating a strong liquidity position[61][69]. Operational Developments - JD Health is focusing on enhancing its online health consumption platform and optimizing its multi-channel business layout to strengthen its market position[12]. - The company is actively expanding its product offerings in the health and wellness sector, including partnerships for digital marketing and patient management services[13]. - The application of large model technology in medical service innovation is a key area of focus for JD Health, reflecting its commitment to technological advancement[12]. - The company launched a new instant delivery service for medication, achieving delivery times as fast as 9 minutes in 18 cities across China[14]. - The online medical service platform has integrated a closed-loop service model of "medical + inspection + diagnosis + medication," enhancing user experience[16]. - The company has expanded its offline services, including the opening of traditional Chinese medicine clinics and health check-up centers[17]. - The company has over 100,000 third-party merchants on its platform, enhancing its supply chain capabilities[25]. Strategic Initiatives - JD Health has engaged in strategic collaborations with local governments to distribute senior consumer vouchers, addressing the diverse health needs of the elderly population[13]. - The company aims to create sustainable value for shareholders and society while pursuing long-term high-quality development[12]. - JD Health partnered with global pharmaceutical companies to launch nearly 30 new specialty drugs online, including innovative treatments for type 2 diabetes and pain management[27]. - The company signed strategic cooperation agreements with brands like Swisse and GNC, enhancing brand influence and user traffic, resulting in a comprehensive sales increase[27]. - The company is committed to leveraging artificial intelligence in healthcare, aligning with national policies promoting health consumption and AI applications[22]. Cost and Expenses - Operating costs increased by 7.6% from RMB 41.7 billion in 2023 to RMB 44.9 billion in 2024, aligned with the growth in retail pharmacy and health business[41]. - Fulfillment expenses grew by 14.1% from RMB 5.3 billion in 2023 to RMB 6 billion in 2024, representing 10.4% of revenue, up from 9.9%[43]. - Sales and marketing expenses increased by 14.8% from RMB 2.7 billion in 2023 to RMB 3 billion in 2024, accounting for 5.2% of revenue[44]. - R&D expenses rose by 8.5% from RMB 1.2 billion in 2023 to RMB 1.3 billion in 2024, maintaining a stable percentage of 2.3% of revenue[45]. - General and administrative expenses decreased by 29.0% from RMB 2 billion in 2023 to RMB 1.4 billion in 2024, reducing its share of revenue from 3.7% to 2.4%[46]. Governance and Management - The company has a strong management team, with the CFO having extensive experience in financial reporting and investment management since joining JD.com in 2015[84]. - The board includes independent directors with diverse backgrounds in finance, healthcare, and technology, ensuring robust governance and strategic oversight[74][79]. - The independent non-executive directors bring significant expertise from various industries, enhancing the company's strategic decision-making capabilities[76][80]. - The company has established a compensation committee to determine the remuneration policies for directors and senior management, ensuring alignment with corporate governance standards[144]. Risks and Compliance - The company has faced various risks and uncertainties, which are detailed in the annual report, highlighting the importance of risk management strategies[92]. - The company faces several risks, including reliance on JD.com and regulatory challenges in the pharmaceutical sales sector[103]. - The company has confirmed compliance with listing rules and understands the responsibilities of being a listed company director[83]. Shareholder Information - JD.com indirectly holds approximately 67.2% of the company's issued share capital as of December 31, 2024[98]. - Liu Qiangdong holds 2,184,655,829 shares, representing 68.30% of the company's equity[126]. - The beneficial ownership data reflects compliance with SEC regulations, including shares that can be acquired through stock options within 60 days[131][136]. - The company has implemented employee stock incentive plans to align the interests of management with those of shareholders[144].

京东健康携手赫力昂启动"无痛中国"生态共建计划，共筑疼痛管理新生态 4月23日，在"健康中国 2030"规划纲要指引下，京东健康与全球消费健康领域领导者赫力昂达成战略合 作，并携手启动"无痛中国"生态共建计划。未来，双方将以疼痛管理为切入点，依托京东健康在数字化 诊疗、全渠道供应链及用户全生命周期服务的核心优势，共同打造覆盖预防、诊断、治疗与康复的健康 服务体系，为国民提供更高效、便捷的疼痛管理解决方案，助力建设健康中国。 京东集团 SEC 委员、京东健康 CEO 金恩林表示："京东健康一直致力于构建全方位的健康生态。此次 与赫力昂的合作，将围绕着科普教育、产品推广、医疗服务等多个维度展开，通过数字化手段和创新模 式，为用户提供更加便捷、高效的疼痛管理解决方案，和更优质的医疗服务，推动疼痛管理领域的变革 与发展。" 赫力昂全球高级副总裁、中国大陆及香港地区总经理顾海英也表示，希望以此次合作升级为契机，进一 步借力京东健康线上线下的全渠道优势，将「医－检－诊－药」的生态闭环推广至更广泛、更细分的疼 痛人群，为消费者提供便捷的购药渠道和专业的医疗咨询服务。 此次京东健康与赫力昂的战略合作，是双方在疼痛管理领域的深 ...

日前，大冢制药旗下第三代酪氨酸激酶抑制剂——英可欣®(通用名：泊那替尼片)在京东健康全网首 发，为慢性髓性白血病(CML)和费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)患者带来了新的治疗选 择。京东健康将依托自身全渠道供应链和全场景医疗健康服务能力，全面提升这款新药的可及性，让更 多患者从中获益。 英可欣®(通用名：泊那替尼片)的上市，进一步推动了我国血液肿瘤治疗领域的进步，为白血病患者特 别是耐药性和难治性患者带来新的治疗曙光。此次在京东健康首发后，患者能够便捷地购买到这款药 品。京东健康将充分发挥冷链物流优势，确保药品在全程恒温无断链的条件下安全送达患者手中。此 外，京东健康还与大冢制药共同开展疾病教育和患者服务项目，通过科普文章、专家视频等内容，提升 公众对白血病等血液肿瘤的健康素养。 京东健康相关负责人表示，英可欣®的全网首发，有望帮助更多白血病患者提高生活质量。京东健康也 将与大冢制药等合作伙伴继续深化合作，帮助更多患者完成高质量的健康管理，享受更加美好的生活。 在临床试验中，英可欣®展现了卓越的疗效和可控的安全性。例如，在OPTIC试验中，接受泊那替尼治 疗的T315I突变型患者在48个月内 ...

Group 1 - Novo Nordisk and JD Health signed a strategic cooperation agreement on April 21, marking a new phase in their collaboration in diabetes and weight management [2] - Approximately 140 million adults in China suffer from diabetes, and around 180 million adults are obese, with rising prevalence rates [2] - The partnership aims to create a public awareness zone for obesity and facilitate one-stop diabetes treatment, enhancing the digital transformation of chronic disease management [2] Group 2 - The collaboration will establish a multi-party dialogue platform to improve accessibility and convenience of quality healthcare services [3] - Utilizing medical big data analysis and AI-assisted diagnosis systems, the partnership aims to develop a comprehensive smart healthcare solution covering the entire cycle from prevention to management [3]

活动现场，许多健康养老好物也与老人们见面。鱼跃电动轮椅轻便灵活，三诺电子血压仪伸手即测，科 大讯飞助听器、迈德斯特电动护理床、医仑特折叠洗澡椅等适老健康产品，让老年人获得便捷舒适的产 品体验。同时，老金磨方黑芝麻丸、银善存多维元素片等健康产品也让老年人有了更多选择。此外，京 东健康的皮肤检测、春季流感检测、护士到家中医按摩调理服务等项目，也被更多活动参与者所了解。 随着我国老龄化进程的加速，银发经济正成为社会关注的焦点。为了更好地服务老年群体，倡导健康养 老的生活方式，4月15日，京东健康在北京陶然亭公园举办了一场别开生面的"老友迎春会"。此次活动 不仅为老年人提供了一个集健康服务、娱乐互动和社交于一体的场合，更是京东健康在推动健康养老产 业高质量发展方面的一次积极探索。 "老友迎春会"精彩纷呈 活动被"点赞" 活动当天，陶然亭公园洋溢着活力与温暖。活动现场设置了多个板块，将健康服务、互动游戏、文艺表 演和养老产品体验有机融合，为老年人带来一场丰富多彩的春日盛会。 在健康服务方面，由三甲医院医生、心理咨询师、京东健康全职营养师、京东护士到家服务团队、之业 堂推拿正骨医师等组成的京东健康专家团，为老年人提供免费 ...

近日，南京正大天晴旗下希诺彤®(通用名：罗沙司他胶囊)与晴万瑞®(通用名：瑞戈非尼)在京东健康全 网首发。这两款重磅新药的上线，将为慢性肾脏病贫血患者及肿瘤患者提供全新的治疗选择。京东健康 将充分发挥其全渠道供应链和全场景医疗健康服务能力，全面提升药品可及性。 当前，慢性肾脏病已经成为中国重要的公共健康问题。贫血是慢性肾脏病患者最常见的并发症之一，肾 性贫血可加速慢性肾脏病进展，增加透析频率、住院率，严重影响生活质量和疾病预后。而在肿瘤治疗 领域，肝癌、肠癌等恶性肿瘤发病率居高不下，晚期患者治疗选择有限，亟需更多创新药物突破治疗瓶 颈。希诺彤®和晴万瑞®的上市，正是针对这些未满足的临床需求，为患者带来新的用药方案。 希诺彤®(罗沙司他胶囊)于2024年12月17日获批上市，适用于慢性肾脏病引起的贫血，涵盖透析和非透 析患者。罗沙司他是一种小分子低氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)类治疗肾性贫血的药物， 具有全新作用机制，与现有常规治疗药物相比，可口服给药，在提高铁利用率、无需静脉补铁等方面具 有临床优势。作为国产罗沙司他，希诺彤®通过了严格的质量和疗效一致性评价，确保了与原研药相当 的疗效和安全性 ...

Core Viewpoint - JD Health collaborates with the Civil Aviation Administration of China to enhance smart healthcare and patient services, aiming to improve hospital operational efficiency and patient experience [1][2]. Group 1: Collaboration Details - The partnership focuses on multiple areas including smart healthcare, supply chain services, and patient services [1]. - JD Health will leverage its strengths in pharmaceutical supply chain, medical big data, and artificial intelligence to provide comprehensive technical support to the Civil Aviation General Hospital [1]. - The collaboration aims to create an AI-based patient service system, utilizing JD Health's large model product, JD Zhuoyi (JOY DOC), to offer solutions like intelligent triage and pre-appointment registration [1]. Group 2: Service Innovations - The initiative promotes a new model of healthcare that combines online and offline services, enhancing convenience for patients [2]. - JD Health will provide online platforms, technical services, and operational support to the Civil Aviation General Hospital, including home nursing services such as intravenous blood collection and post-operative care [1][2]. - The collaboration will also explore the integration of JD Logistics' supply chain capabilities to offer comprehensive pharmaceutical logistics services, ensuring efficient access to necessary medications and materials [2]. Group 3: Future Directions - Both parties plan to deepen their cooperation and explore more innovative models and services to provide convenient, efficient, and high-quality healthcare services [2].

Core Insights - The 2025 Wuzhen Health Conference, featuring a special session by JD Health, focused on the theme of "Unlocking New Growth Curves through Digital Transformation" in the pharmaceutical and health industry [1] - JD Health is leveraging innovative practices and comprehensive growth strategies to invigorate the pharmaceutical health sector amid a dual-driven transformation by policy and market forces [1] Industry Overview - The pharmaceutical industry is undergoing significant changes driven by both policy and market dynamics, with the normalization of national drug procurement accelerating the outflow of prescriptions [1] - The opening of online medical insurance payment policies is expected to release a market potential worth trillions, while the awakening of user health awareness is creating diverse demands [1] Company Strategy - JD Health, as a leading pharmaceutical retail channel, is building an ecological closed loop through four capabilities: "omni-channel marketing, full-scenario coverage, infinite shelf, and AI-driven" [2] - The company has achieved a 45% extension in the chronic disease medication cycle (DOT) and has successfully launched multiple popular products through its "infinite shelf" model [2] Marketing and User Engagement - JD Health has broken down traffic barriers by achieving efficient collaboration between online and offline channels, providing brands with precise user reach and effective traffic conversion [2] - The company utilizes the Jingzhun Tong platform to offer brands controllable advertising marketing tools, aiding in user engagement and brand sales growth [2] Service Capabilities - JD Health has established a service closed loop encompassing "medicine + testing + diagnosis + drugs" through its internet hospital platform and home testing services [3] - The company plans to expand its capabilities in niche areas such as traditional Chinese medicine and DTP pharmacies, aiming to create an integrated online and offline super pharmacy ecosystem [3] Future Outlook - The special session at the 2025 Wuzhen Health Conference showcased JD Health's innovative practices and provided valuable insights for the future development of the pharmaceutical health industry [3] - Through digital upgrades, user experience reconstruction, and comprehensive growth strategies, JD Health is collaborating with industry partners to pioneer a new future in the pharmaceutical health sector [3]